EP1230259A1 - S-allylmercaptoglutathione and uses thereof - Google Patents

S-allylmercaptoglutathione and uses thereof

Info

Publication number
EP1230259A1
EP1230259A1 EP00976230A EP00976230A EP1230259A1 EP 1230259 A1 EP1230259 A1 EP 1230259A1 EP 00976230 A EP00976230 A EP 00976230A EP 00976230 A EP00976230 A EP 00976230A EP 1230259 A1 EP1230259 A1 EP 1230259A1
Authority
EP
European Patent Office
Prior art keywords
allicin
gssa
gsh
reaction
allylmercaptoglutathione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00976230A
Other languages
German (de)
French (fr)
Inventor
Talia Miron
Aharon Rabinkov
Lev Weiner
David Mirelman
Meir Wilchek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of EP1230259A1 publication Critical patent/EP1230259A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Definitions

  • the present invention relates to a new glutathione derivative, namely S- allylmercaptoglutathione, its preparation and pharmaceutical compositions comprising it.
  • BAPNA N- ⁇ -benzoyl-DL-arginine p-nitroanilide
  • Biradical bis (2,2,5,5- tetramethyl-3-imidazoline-l-oxyl-4-yl) disulfide
  • CSSA S-allylmercapto cystein
  • DAD diallyl disulfide
  • DTT dithiothreitol
  • DMPO 5,5'-dimethyl-l-pyrroline N- oxide
  • DTNB 5,5'-dithio-bis (2-nitrobenzoic acid
  • ESR electron spin resonance
  • GSH reduced glutathione
  • GSSA S-allylmercaptoglutathione
  • GSSG oxidized glutathione
  • LPO lipid peroxides production
  • NTB 2-nitro-5-thiobenzoate
  • PBS phosphate-buffered saline
  • RBC red blood cell
  • SUV small unilamellar phospholipid vesicles
  • TBA TBA
  • Allium sativum garlic sativum
  • allicin diallyl thiosulfmate
  • Allicin is produced during the crushing of garlic cloves by the interaction between the non-protein amino acid alliin (S-allyl-L-cysteine sulfoxide) and the enzyme alliinase.
  • Allicin is a precursor of a number of secondary products formed in aged garlic and crushed garlic preparations. Allicin possesses various biological activities among which antibacterial, antifungal and antiparasitic effects are included [Ankri et a., 1997; Koch and Lawson, 1996; Feldberg et al., 1988; Cavallito et al., 1944). In addition to that it reduces serum cholesterol and triglycerides levels as well as atherosclerotic plaque formation and platelet aggregation, it inhibits cancer promotion and decreases ocular pressure [Koch and Lawson, 1996; Chu et al., 1993]. Allicin rapidly disappears after injection into the blood [Lawson and Wang, 1993; Freeman and Kodera, 1995].
  • CSSA Recently antioxidant, antiproliferative, decreasing ocular pressure activities of CSSA have been demonstrated [Imai et al., 1994; Lee et al, 1994; Sigounas et al. , 1997a, 1997b; Pinto et al., 1997; Chu et al., 1999]. CSSA revealed antiproliferative effect on different cell lines whereas S-allylcysteine had no effect [Lee et aL, 1994] The concentration of GSH in the blood is about 100-fold higher than that of cysteine, therefore GSH remains as the main candidate for the interaction with allicin in vivo.
  • GSSA S-allylmercaptoglutathione
  • the present invention thus relates to the novel synthetic glutathione derivative, S-allylmercaptoglutathione, and to salts thereof, to its preparation by reaction of glutathione with allicin or with diallyl disulfide, and to pharmaceutical compositions comprising it.
  • salts of GSSA are also included in the invention.
  • salts refers both to salts of carboxyl groups and to acid addition salts of the amino group.
  • Salts of a carboxyl group may be formed by methods known in the art and include inorganic salts such as salts with alkali metals, e.g. sodium or potassium, and salts with ammonia or with organic bases such as with amines.
  • Acid addition salts include salts with mineral acids such as hydrochloric acid or sulfuric acid and salts with organic acids such as acetic acid.
  • compositions comprising S-allylmercaptoglutathione are useful for the treatment of several disorders including atherosclerosis, coronary artery diseases, thrombosis, high levels of cholesterol and blood lipids, high blood pressure, control of weight, Alzheimer disease, glaucoma, cancer and inflammatory disorders such as colitis.
  • Fig. 1 shows the kinetics of the reaction of allicin with GSH, monitored by appearance of S-allylmercaptoglutathione (GSSA) (white circles) and disappearance of allicin (black circles).
  • GSSA S-allylmercaptoglutathione
  • the initial concentration of GSH was 1 .2 mM and that of allicin 0.7 mM.
  • the reaction was carried out at pH 7.0.
  • Fig. 2 shows estimation of concentration of intracellular thiols under incubation, as a function of allicin added to a 1% RBC suspension. Concentration of SH-groups was estimated by ESR with Biradical.
  • Fig. 3 shows the kinetics of appearance of GSSA in RBC at 37°iC after treatment with allicin. Allicin-treated RBC were washed with cysteine and PBS to remove external allicin, then treated with trichloroacetic acid. The concentration of GSSA was assayed in the supernatant.
  • Fig. 4 shows GSSA formation rate in the allicin/GSH reaction mixture ( 1 mM GSH incubated with 0.7, 1.0 or 1.3 mM allicin at pH 5.0, at room temperature) as function of allicin concentration.
  • the initial amount of GSSA produced was followed by HPLC analysis at different time intervals after dilution with HPLC acidic running buffer.
  • Fig. 5 shows the kinetics of formation of GSSA in the allicin/GSH reaction mixture (0.25 mM GSH incubated with 1.068 mM allicin) at pH 6.0 and 7.0. At different time intervals, aliquots were diluted with 0.1% formic acid in 60% methanol, and assayed by HPLC.
  • Fig. 6 shows GSSA formation rate in the allicin/GSH reaction mixture (0.25 mM GSH incubated with 1 mM allicin at room temperature) as a function of pET. Each column represents the mean ⁇ S.D. of three determinations done at the same pH.
  • Fig. 7 shows papain inhibition by GSSA.
  • the residual activity of the inhibited enzyme was assayed at pH 6.5.
  • Activity is expressed as % of enzyme activity of non-inhibited papain.
  • Figs. 8A-8B show ESR spectra of spin-adduct of DMPO with OH radical formed in the Fenton system, in the absence of an antioxidant (Fig. 8A) and in the presence of 1 mM GSSA (Fig. 8B).
  • Fig. 9 shows that allicin, CSSA and GSSA inhibit the appearance of -OHradicals and thus decrease the formation of DMPO- -OH spin adduct.
  • Fig. 10 shows lipid peroxides (LPO) production (%) in fetal rat brain slices during 30 min incubation in presence of 0.1 mM of alliin, allicin, GSSA, GSH or vitamin E, as determined by the thiobarbituric acid assay (production of thiobarbituric acid reactive substance - TBARS).
  • Fig. 11 shows the antioxidant effect of alliin, allicin, GSSA and vitamin E on LPO production by fetal rat brain slices, determined as in Fig. 10 above, as function of reagent concentration.
  • Fig. 12 shows the effect of concentrations of allicin (squares) and GSSA (diamonds) on the proliferation of MCF-7 human mammary cancer cells. Measurements were done after three days of treatment at various concentrations.
  • Fig. 13 shows the effect of 32 ⁇ M of GSSA, 32 ⁇ M of allicin or medium only, on the proliferation of MCF-7 cells.
  • GSSH was synthesized for the first time and its SH-modifying and antioxidant properties were demonstrated.
  • GSSA is prepared by reaction between allicin and GSH. This reaction is rather fast with K of bimolecular reaction apparently 3.0 M' ⁇ sec - 1 . It is pH- dependent revealing strong dependence on real concentration of GS ⁇ , indicating that products of allicin transformation which include a thioallyl radical possess some of allicin activities due to its SH-modifying effect.
  • the invention further includes pharmaceutical compositions comprising GSSA and a pharmaceutically acceptable carrier.
  • GSSA can be incorporated in conventional, solid and liquid pharmaceutical formulations (e.g- tablets, capsules, caplets, injectable and orally administerable solutions) for use in treating mammals, including humans, suffering from several disorders including atherosclerosis, coronary artery diseases, thrombosis, high levels of cholesterol and blood lipids, high blood pressure, control of weight, Alzheimer disease, glaucoma, cancer and inflammatory disorders such as colitis.
  • the GSSA compositions can be used for all uses known for allicin, excepting as antibacterial.
  • the phannaceutical composition of the invention is in a form for oral administration, for example as an aqueous solution.
  • DAD Diallyl disulfide
  • Papain (EC 3.4.22.2) was obtained from Boehringer Mannheim (Germany). Alcohol dehydrogenase from. Thermoanaerobium brockii (TBAD) (EC 1.1.1.2) was the kind gift of Dr. M. Peretz and Dr. Y. Burstein, Weizmann Institute of Science, Rehovot, Israel. Egg phosphatidylcholine (PC) was purchased from Lipid Products (South Nutfield, UK). Cholesterol (extra pure) was from Merck (Darmstadt, Germany).
  • Symmetrical stable nitroxyl biradical containing disulfide bond bis (2,2,5,5- tetramethyl-3-imidazoline-l-oxyl-4-yl) disulfide (Biradical) synthesized according to [Kitz and Wilson, 1962] was a kind gift of Dr.V. Martin (Lipitek Int. Inc, San Antonio, Texas, USA). All other reagents were of analytical grade.
  • Alliin was synthesized as described in Rabinkov et al., 1998. Allicin was produced by applying synthetic alliin onto immobilized alliinase as described in published PCT Patent Application No. WO 97/39115. CSSA was synthesized from cysteine and allicin and isolated as described in Rabinkov et al., 1998. NTB was prepared according to Degani and Patchornik, 1971.
  • Papain activation was carried out by dilution (1 : 10) of papain suspension with 50 mM Na acetate, 2 mM EDTA, pH 6.1 (Na acetate/EDTA buffer) in presence of 2.5 mM dithiothreitol (DTT) for 30 min at room temperature. Excess of DTT was removed by gel filtration on Sephadex G-25 pre-equilibrated with Na acetate/EDTA buffer. The activity of papain was determined at room temperature by following the hydrolysis of BAPNA at pH 6.1, in room temperature at 382 nm [Angelides and Fink, 1979]. (e) Assay of TB AD activity
  • the rate constant for the reaction of allicin (0.7-1.3 mM) and GSH (1 mM) was obtained in 10 mM phosphate/citrate buffer (pH 5.0) or in 0.1 M NaCl, 0.01 M Na phosphate buffer (pH 7.0).
  • the initial rate of GSSA appearance was monitored by HPLC. At various time intervals, samples were diluted with HPLC running buffer and analyzed by HPLC. For calculation the following equation was used: d[GSSA]/dt - [Allicin]x[GSH] where: d[GSSA]/dt is the initial rate of GSSA appearance; K is the bimolecular rate constant; [Allicin], [GSH] are the initial concentrations of allicin and GSH.
  • Small unilamellar phospholipid vesicles were made either from egg phosphatidylcholine (PC) or dimyristoylphosphatidylcholine (DMPC) and cholesterol.
  • PC egg phosphatidylcholine
  • DMPC dimyristoylphosphatidylcholine
  • cholesterol content was 25%.
  • Cholesterol was dissolved in CHCl 3 /MeOH (2:1 v/v). The cholesterol solution was added to the dry lipid.
  • a film of 2.5-5 mg lipid/glass vial was prepared by evaporating the solvents under a stream of nitrogen, followed by 3 h drying under high vacuum.
  • SUV containing GSH were obtained by sonication according to Shin et al., 1996, as follows: GSH solution (0.2 M in 0.05 M NaCl, pH 7.0) was added to the dried film, mixed by vortex and sonicated for 10-30 min in a bath-type sonicator (G1125SP1, Laboratory Supplies Co. Inc., New York, NY). Final phospholipid concentration was either 5 or 10 mg/ml.
  • Fresh human blood in the presence of heparin was washed three times with PBS. RBCs were collected after centrifugation (2000 rpm, 5 min) and resuspended in PBS. A 10% or 1% (vol/vol) suspension of RBC in PBS was used in the experiments.
  • Measurements were performed in a flat cell of the Bruker ER-200 D-SRC spectrometer.
  • the experimental conditions included the following: field, 3500 G; sweep width, 100 G; receiver gain, 2x10 ⁇ ; microwave power, 20 mW; modulation amplitude, 0.8 G.
  • DMPO was purified as described in Buettner and Oberley, 1978.
  • the sample contained H2O2 ( 1 mM), Fe ⁇ (EDTA)2 (0.8 mM ), DMPO (100 mM), in 20 mM sodium phosphate buffer (pH 7.4)) and NaCl (0.2 M), (final volume 0.2 ml)
  • H2O2 1 mM
  • Fe ⁇ (EDTA)2 0.8 mM
  • DMPO 100 mM
  • 20 mM sodium phosphate buffer (pH 7.4) mM sodium phosphate buffer (pH 7.4)
  • NaCl 0.2 M
  • NMR spectra were collected on a Bruker AMX-400 spectrometer. Analysis of allicin and CSSA structures was performed as described in Rabinkov et al., 1998. The product of the interaction between allicin and glutathione was isolated and dissolved in deuterated water and solutions of 10 mM were prepared. The pH was adjusted to 6.5 using KOD. ID *H (with water signal suppression) and 13 C spectra were collected at 25 ⁇ C. Structure analysis of the product obtained was performed as described previously (Miron et al., 1998; Rabinkov et al., 1998). Resonance multiplicities for * 3 C were established by acquiring DEPT spectra. For the DEPT sequence, the width of a 3 C 90° pulse was 7ms, that of a ⁇ H 90° was 12.8 ms, and the (2J)"1 delay was set to 3.45 ms.
  • the 2D COSY45 H-1H shift-correlated spectra was recorded using a data size of 512 (tl)x 2048 (t2) with a spectral width of 1400 Hz.
  • the HMQC spectra were recorded using a pulse sequence (invbtp in the Bruker software) which included the bilinear rotational decoupling (BIRD) pulse to invert the magnetization of protons not coupled to l ⁇ C.
  • the spectra were collected with 2048 (t2) x 256 (tl) data points. Spectral widths of 1400 and 11000 Hz were used in the
  • F2 (IK) and FI ( ⁇ C) domains were multiplied in both dimensions by a 90°- shifted sine bell or Gaussian transformation function and generally zero-filled to 512 in tl dimension prior to Fourier transformation.
  • the delay Di was set to 3.4 ms while D2 was empirically optimized at 600ms.
  • GSH Small unilamellar phospholipid vesicles (SUV) containing GSH were prepared in order to show allicin's propensity to permeate the lipid bilayer membrane.
  • GSH the main intracellular thiol of mammalian cells, is highly hydrophilic and therefore cannot pass lipid membranes.
  • Red blood cells are naturally occurring membrane vesicles in which GSH is present at a concentration of 1-2 mM.
  • the amount of thiols in PBS-washed human RBC was measured either by the noninvasive ESR technique with Biradical developed earlier by Weiner (1995), or directly after trichloroacetic acid (TCA) precipitation of the RBC and assay with DTNB at pH 7.0 (Table 4).
  • the total concentration of thiol-containing compounds estimated by the two independent methods were very similar (about 2 mM) and are in a good agreement with data reported by others (Vina et al., 1995).
  • the advantage of the ESR method is that it enables monitoring of the decrease of thiol concentration in cells after short exposure to allicin.
  • Allicin (up to 2.5 x 10 "5 M final concentration) was added to a 1% washed RBC suspension in an Eppendorf tube. After 1 -2 min at room temperature the Biradical was added (10 "4 M final concentration) and the content of residual thiol concentration was monitored. As shown in Fig. 2, allicin penetrates through the RBC membrane and reacts with intracellular thiols in a concentration dependent manner
  • GSSA S-allylmercaptoglutathione
  • GSH (1 mM) was incubated with allicin (0.7 mM to 1.3 mM) in 10 mM citrate phosphate buffer pH 5.0, at room temperature.
  • the initial amount of GSSA produced was followed by HPLC analysis at different time intervals after dilution with HPLC acidic running buffer.
  • the appearance of the product on HPLC during the reaction enabled us to follow the kinetic of interaction of allicin with GSH.
  • the bimolecular kinetic constant of the reaction at pH 5 was determined at allicin concentrations of 0.7, 1.0 and 1.3 mM. The results are shown in Fig. 4 and in
  • the SH-modifying activity of GSSA and CSSA was determined in the same enymatic systems as was described earlier for allicin (Rabinkov et al., 1998), namely, in SH-protease papain, where a SH-group (Cys25) J s located in the active site, and in alcohol dehydrogenase from the thermophylic bacteria Thermoanaerobium brockii (TBAD), where a SH-group (Cys20 ) ⁇ s located very close to the NADP + - binding site (Korkhin et al., 1998).
  • the Cys25 of papain is located on the protein surface, on the groove between the two lobes of the protein, and therefore is available for chemical modification.
  • Each TBAD subunit contains one free SH-group on the protein surface. Chemical modification of that group inhibits dramatically the enzymatic activity (Peretz et al., 1997; Rabinkov et al., 1998).
  • DTT-activated and gel-filtered papain (papain-SH) was inactivated by GSSA (2.0 mM, 4.0 mM. 9.0 mM) in 50 mM Na acetate buffer pH 6.2 containing 2 mM EDTA.
  • the residual activity of the inhibited enzyme was assayed at pH 6.5 and recorded as described in Material and Methods, section (d). Activity is expressed as % of enzyme activity of non- inhibited papain.
  • incubation of activated papain with GSSA led to rapid loss of enzymatic activity.
  • CSSA data not shown
  • allicin Rosin et al, 1998
  • the loss of activity was time dependent.
  • the rates of enzyme inactivation depend on the initial disulfide's concentration. As follows from these experiments, CSSA and GSSA, the natural products of allicin transformation, show pronounced SH modifying activity.
  • Example 7 Effect of GSSA on LPO production by fetal rat brain slices ex vivo
  • the antioxidant activity of GSSA was investigated in tissues using fetal rat brain slices model ex vivo under iron-induced oxidative stress by determination of the lipid peroxides level as described in Materials and Methods, section (m).
  • the effect of GSSA was compared with activities of alliin, allicin, GSH, GSSG, 2- deoxyribose and vitamin E.
  • LPO production (%) in fetal rat brain slices was determined during 30 min incubation in presence of 0.1 mM of the various reagents by the TBA assay as described in Materials and Methods, section (m). As shown in Fig. 10, no significant antioxidant activity was observed after incubation of brain slices with alliin.
  • MCF-7 human mammary cancer cells were grown in DMEM medium containing 0.6 ⁇ g/ml insulin. The medium was supplemented with penicillin (10O U/ml), streptomycin (0.1 mg/ml) nystatin (12.5 ⁇ g/ml), and 10% FCS. Cells were seeded into 6-multiwell plates (170,000 cells per well) or 96-multiwell plates (5,000 cells per well) or 100 mm dish (1,500,00 cells per dish) in medium containing 3% FCS. One day later the medium was changed to one containing either only medium or allicin or GSSA, and the media were replaced daily.
  • Lipid peroxides are generated by the fetal rat brain after episodes of global ischemia in utero, Neurochemical Research, 22: 201-208.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

S-Allylmercaptoglutathione of formula (I) is prepared by reaction of glutathione with allicin or with diallyl disulfide and can be used in pharmaceutical compositions for the treatment of atherosclerosis, coronary artery diseases, thrombosis, high levels of cholesterol and blood lipids, high blood pressure, control of weight, Alzheimer disease, glaucoma, cancer and inflammatory disorders.

Description

S-ALLYLMERCAPTOGLUTATHIONE AND USES THEREOF
Field of the Invention The present invention relates to a new glutathione derivative, namely S- allylmercaptoglutathione, its preparation and pharmaceutical compositions comprising it.
Abbreviations BAPNA: N-α-benzoyl-DL-arginine p-nitroanilide; Biradical: bis (2,2,5,5- tetramethyl-3-imidazoline-l-oxyl-4-yl) disulfide; CSSA: S-allylmercapto cystein; DAD: diallyl disulfide; DTT: dithiothreitol; DMPO: 5,5'-dimethyl-l-pyrroline N- oxide; DTNB: 5,5'-dithio-bis (2-nitrobenzoic acid); ESR: electron spin resonance; GSH: reduced glutathione; GSSA: S-allylmercaptoglutathione; GSSG: oxidized glutathione; LPO: lipid peroxides production; NTB: 2-nitro-5-thiobenzoate; PBS: phosphate-buffered saline; RBC: red blood cell; SUV: small unilamellar phospholipid vesicles; TBA: thiobarbituric acid; TBAD: alcohol dehydrogenase from Thermoanaerobium brockii; TBARS: thiobarbituric acid reactive substance.
Background of the Invention
Many beneficial health related biological effects of garlic (Allium sativum) are attributed to its characteristic organosulfur compounds. The best known and most extensively studied is allicin (diallyl thiosulfmate), the principal active substance of fresh garlic extract, which is responsible for garlic's typical pungent smell. Allicin is produced during the crushing of garlic cloves by the interaction between the non-protein amino acid alliin (S-allyl-L-cysteine sulfoxide) and the enzyme alliinase.
Allicin is a precursor of a number of secondary products formed in aged garlic and crushed garlic preparations. Allicin possesses various biological activities among which antibacterial, antifungal and antiparasitic effects are included [Ankri et a., 1997; Koch and Lawson, 1996; Feldberg et al., 1988; Cavallito et al., 1944). In addition to that it reduces serum cholesterol and triglycerides levels as well as atherosclerotic plaque formation and platelet aggregation, it inhibits cancer promotion and decreases ocular pressure [Koch and Lawson, 1996; Chu et al., 1993]. Allicin rapidly disappears after injection into the blood [Lawson and Wang, 1993; Freeman and Kodera, 1995]. This rather unstable compound has been suggested by Lawson and coworkers to transform rapidly into secondary products (in vivo), such as allylmercaptan and others [Koch and Lawson, 1996; Lawson and Wang, 1993]. At present a variety of biological effects of allicin is attributed to both antioxidant activity and modification of SH- dependent activities [Wills, 1956; Prasad et al., 1995]. These activities have been confirmed by us in model systems [Rabinkov et al., 1998; Miron et al., 1998] . Recently the inhibitory effect of allicin on NO formation was also demonstrated [Dirsch et al., 1998] . In addition to that, allicin affects the processing of DNA and RNA synthesis [Feldberg et al., 1988], signal transduction and apoptosis. All the effects described above are mainly intracellular. Therefore the question arose: how does allicin permeate through the plasma membrane and take part in intracellular processes?
The observation of fast disappearance of allicin from the blood on one hand and its high efficacy on the other, lead to the question about the ability of allicin- transformed products to generate extra- and intracellular processes. The most abundant non-protein thiols which can potentially interact with allicin are reduced glutathione (GSH) and cysteine. S-allylmercaptocysteine (CSSA) is known already as the product formed when cysteine reacts with allicin [Cavallito et al., 1944] . Aged garlic extract contains this compound as one of its active components . Recently antioxidant, antiproliferative, decreasing ocular pressure activities of CSSA have been demonstrated [Imai et al., 1994; Lee et al, 1994; Sigounas et al. , 1997a, 1997b; Pinto et al., 1997; Chu et al., 1999]. CSSA revealed antiproliferative effect on different cell lines whereas S-allylcysteine had no effect [Lee et aL, 1994] The concentration of GSH in the blood is about 100-fold higher than that of cysteine, therefore GSH remains as the main candidate for the interaction with allicin in vivo.
Summary of the Invention
According to the present invention, while studying the permeability of allicin through lipid bilayers of phospholipid vesicles as well as through natural membranes of red blood cells (RBCs), using its interaction with internally entrapped thiol containing compounds such as glutathione (GSH), it was found that when allicin interacts with GSH according to the Reaction 1 below, the reaction product formed is S-allylmercaptoglutathione (hereinafter GSSA):
2 GSH + CH2=CH-CH2 + H O
Glutathione Allicin S-Allylmercaptoglutathione
Reaction 1, wherein G is the residue of glutathione. The complete formula of GSSA is as follows:
H2NCHCH2CH2CONHCHCONHCH2COOH
COOH CH2-S-S-CH2-CH=CH2
The present invention thus relates to the novel synthetic glutathione derivative, S-allylmercaptoglutathione, and to salts thereof, to its preparation by reaction of glutathione with allicin or with diallyl disulfide, and to pharmaceutical compositions comprising it.
Also included in the invention are salts of GSSA. The term "salts", as used herein, refers both to salts of carboxyl groups and to acid addition salts of the amino group. Salts of a carboxyl group may be formed by methods known in the art and include inorganic salts such as salts with alkali metals, e.g. sodium or potassium, and salts with ammonia or with organic bases such as with amines. Acid addition salts include salts with mineral acids such as hydrochloric acid or sulfuric acid and salts with organic acids such as acetic acid.
The pharmaceutical compositions comprising S-allylmercaptoglutathione are useful for the treatment of several disorders including atherosclerosis, coronary artery diseases, thrombosis, high levels of cholesterol and blood lipids, high blood pressure, control of weight, Alzheimer disease, glaucoma, cancer and inflammatory disorders such as colitis.
Brief Description of the Drawings Fig. 1 shows the kinetics of the reaction of allicin with GSH, monitored by appearance of S-allylmercaptoglutathione (GSSA) (white circles) and disappearance of allicin (black circles). The initial concentration of GSH was 1 .2 mM and that of allicin 0.7 mM. The reaction was carried out at pH 7.0.
Fig. 2 shows estimation of concentration of intracellular thiols under incubation, as a function of allicin added to a 1% RBC suspension. Concentration of SH-groups was estimated by ESR with Biradical.
Fig. 3 shows the kinetics of appearance of GSSA in RBC at 37°iC after treatment with allicin. Allicin-treated RBC were washed with cysteine and PBS to remove external allicin, then treated with trichloroacetic acid. The concentration of GSSA was assayed in the supernatant.
Fig. 4 shows GSSA formation rate in the allicin/GSH reaction mixture ( 1 mM GSH incubated with 0.7, 1.0 or 1.3 mM allicin at pH 5.0, at room temperature) as function of allicin concentration. The initial amount of GSSA produced was followed by HPLC analysis at different time intervals after dilution with HPLC acidic running buffer.
Fig. 5 shows the kinetics of formation of GSSA in the allicin/GSH reaction mixture (0.25 mM GSH incubated with 1.068 mM allicin) at pH 6.0 and 7.0. At different time intervals, aliquots were diluted with 0.1% formic acid in 60% methanol, and assayed by HPLC. Fig. 6 shows GSSA formation rate in the allicin/GSH reaction mixture (0.25 mM GSH incubated with 1 mM allicin at room temperature) as a function of pET. Each column represents the mean ± S.D. of three determinations done at the same pH.
Fig. 7 shows papain inhibition by GSSA. The residual activity of the inhibited enzyme was assayed at pH 6.5. Activity is expressed as % of enzyme activity of non-inhibited papain.
Figs. 8A-8B show ESR spectra of spin-adduct of DMPO with OH radical formed in the Fenton system, in the absence of an antioxidant (Fig. 8A) and in the presence of 1 mM GSSA (Fig. 8B).
Fig. 9 shows that allicin, CSSA and GSSA inhibit the appearance of -OHradicals and thus decrease the formation of DMPO- -OH spin adduct.
Fig. 10 shows lipid peroxides (LPO) production (%) in fetal rat brain slices during 30 min incubation in presence of 0.1 mM of alliin, allicin, GSSA, GSH or vitamin E, as determined by the thiobarbituric acid assay (production of thiobarbituric acid reactive substance - TBARS). Fig. 11 shows the antioxidant effect of alliin, allicin, GSSA and vitamin E on LPO production by fetal rat brain slices, determined as in Fig. 10 above, as function of reagent concentration.
Fig. 12 shows the effect of concentrations of allicin (squares) and GSSA (diamonds) on the proliferation of MCF-7 human mammary cancer cells. Measurements were done after three days of treatment at various concentrations.
Fig. 13 shows the effect of 32 μM of GSSA, 32 μM of allicin or medium only, on the proliferation of MCF-7 cells.
Detailed Description of the Invention We have recently shown that the beneficial effects of allicin on health may stem from its interaction with SH-containing molecules such as enzymes and/or its high antioxidant activity [Ankri et al., 1997; Rabinkov et al, 1998; Miron et al., 1998]. Free thiol-containing compounds are usually intracellular, since extracellular thiols are in most cases oxidized to disulfide by the environmental molecular oxygen. Allicin rapidly interacts with free thiols abundantly present in tissues such as GSH, the major intracellular thiol. The high SH-modifying reactivity of allicin can also be the main reason for its fast disappearance from the blood.
Therefore, the manner in which allicin can penetrate cell membranes and interact with intracellular thiols was investigated according to the present invention. Low molecular weight thiol-containing compounds such as GSH and 2- nitro-5-thiobenzoate (NTB) were entrapped in lipid vesicles and red blood cells were used as natural containers of GSH. Thus the interaction of GSH and NTB with externally added allicin could be studied. Based on the kinetics of this reaction, it was clearly shown that the interaction of allicin with the low molecular weight thiols entrapped in the vesicles was not dependent on the release of GSH and NTB from vesicles, since the reaction product, GSSA, was detected in the vesicle fraction after gel filtration at the end of the reaction.
It was further observed that allicin freely permeates through phospholipid bilayers and interacts with the SH groups. The reaction rate of allicin with the SH- containing molecules after crossing the membrane was the same as in solution. Fast diffusion and permeation of allicin across human red blood cell membranes was also demonstrated. The high permeability of allicin through membranes may greatly enhance the intracellular interaction with thiols.
According to the present invention, GSSH was synthesized for the first time and its SH-modifying and antioxidant properties were demonstrated.
GSSA is prepared by reaction between allicin and GSH. This reaction is rather fast with K of bimolecular reaction apparently 3.0 M' ^sec- 1. It is pH- dependent revealing strong dependence on real concentration of GS~, indicating that products of allicin transformation which include a thioallyl radical possess some of allicin activities due to its SH-modifying effect.
Study of the antioxidant effect of GSSA in vitro using the Fenton system revealed that GSSA has high ability to prevent formation of OH radicals. In experiments on fetal rat brain slices, the Fe2+-induced TBARS production assay was utilized as an indicator of oxidative stress in the brain. The study of the effect of allicin and GSSA on the capacity of fetal brain to generate peroxides, both under normal and after ischemia-induced stress conditions, showed that addition of 0.1 mM GSSA was sufficient to reduce TBARS production by about 40%, while 0.1 mM of either vitamin E or allicin exhibited similar inhibition effect (about 5O %) against iron-induced lipid peroxidation in fetal brain slices. This indicates that the SH-modifying activity of GSSA may be attributed to antioxidant capacity as well and that GSSA may be clinically useful as potential antioxidant.
The invention further includes pharmaceutical compositions comprising GSSA and a pharmaceutically acceptable carrier. For this purpose GSSA can be incorporated in conventional, solid and liquid pharmaceutical formulations (e.g- tablets, capsules, caplets, injectable and orally administerable solutions) for use in treating mammals, including humans, suffering from several disorders including atherosclerosis, coronary artery diseases, thrombosis, high levels of cholesterol and blood lipids, high blood pressure, control of weight, Alzheimer disease, glaucoma, cancer and inflammatory disorders such as colitis. In principle, the GSSA compositions can be used for all uses known for allicin, excepting as antibacterial. In a preferred embodiment, the phannaceutical composition of the invention is in a form for oral administration, for example as an aqueous solution.
The invention will now be illustrated by the following non-limiting Examples.
EXAMPLES
Materials and Methods (a) Materials
Reduced glutathione (GSH), L-cysteine, DTT, N- -Benzoyl-DL-arginine p- nitroanilide (BAPNA), 5,5'-dimethyl-l-pyrroline N-oxide (DMPO), FeSO (7H20), α-Tocopherol (Vitamin E), oxidized glutathione (GSSG), dimyristoyl phosphatidylcholine (DMPC), calcein and 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Diallyl disulfide (DAD) was purchased from Aldrich. Papain (EC 3.4.22.2) was obtained from Boehringer Mannheim (Germany). Alcohol dehydrogenase from. Thermoanaerobium brockii (TBAD) (EC 1.1.1.2) was the kind gift of Dr. M. Peretz and Dr. Y. Burstein, Weizmann Institute of Science, Rehovot, Israel. Egg phosphatidylcholine (PC) was purchased from Lipid Products (South Nutfield, UK). Cholesterol (extra pure) was from Merck (Darmstadt, Germany). Symmetrical stable nitroxyl biradical containing disulfide bond, bis (2,2,5,5- tetramethyl-3-imidazoline-l-oxyl-4-yl) disulfide (Biradical) synthesized according to [Kitz and Wilson, 1962] was a kind gift of Dr.V. Martin (Lipitek Int. Inc, San Antonio, Texas, USA). All other reagents were of analytical grade.
(b) Synthesis of alliin, allicin, S-allylmercaptocystein (CSSA), and NTB
Alliin was synthesized as described in Rabinkov et al., 1998. Allicin was produced by applying synthetic alliin onto immobilized alliinase as described in published PCT Patent Application No. WO 97/39115. CSSA was synthesized from cysteine and allicin and isolated as described in Rabinkov et al., 1998. NTB was prepared according to Degani and Patchornik, 1971.
(c) Separation of alliin, GSSA and allicin by HPLC
Quantitative determinations of alliin, GSSA and allicin, were performed in an LKB HPLC system with the SP 4290 integrator (Spectraphysics). The separation was achieved on a LiChrosorb RP-18 (7 μm) column using 60% methanol in water containing 0.1 % formic acid as an eluant. Flow rate was 0.56 ml/min.
(d) Assay of papain activity.
Papain activation was carried out by dilution (1 : 10) of papain suspension with 50 mM Na acetate, 2 mM EDTA, pH 6.1 (Na acetate/EDTA buffer) in presence of 2.5 mM dithiothreitol (DTT) for 30 min at room temperature. Excess of DTT was removed by gel filtration on Sephadex G-25 pre-equilibrated with Na acetate/EDTA buffer. The activity of papain was determined at room temperature by following the hydrolysis of BAPNA at pH 6.1, in room temperature at 382 nm [Angelides and Fink, 1979]. (e) Assay of TB AD activity
TBAD activity was assayed at room temperature by following the foraiation rate of NADPH from NADP+ at 340 mn (E 340 = 6.225 mM"1 cm -1) [Peretz and Burstein, 1989] .
(f) Inhibitory analysis
Kinetic analysis of irreversible inactivation of the SH-containing enzymes papain and TBAD were calculated according to Kitz and Wilson, 1962.
(g) Determination of rate constants
The rate constant for the reaction of allicin (0.7-1.3 mM) and GSH (1 mM) was obtained in 10 mM phosphate/citrate buffer (pH 5.0) or in 0.1 M NaCl, 0.01 M Na phosphate buffer (pH 7.0). The initial rate of GSSA appearance was monitored by HPLC. At various time intervals, samples were diluted with HPLC running buffer and analyzed by HPLC. For calculation the following equation was used: d[GSSA]/dt - [Allicin]x[GSH] where: d[GSSA]/dt is the initial rate of GSSA appearance; K is the bimolecular rate constant; [Allicin], [GSH] are the initial concentrations of allicin and GSH.
(h) Preparation of phospholipid vesicles
Small unilamellar phospholipid vesicles (SUV) were made either from egg phosphatidylcholine (PC) or dimyristoylphosphatidylcholine (DMPC) and cholesterol. In the case of SUV made from PC, the concentration of cholesterol was 17% mol/mol. In the case of SUV made from DMPC, cholesterol content was 25%. mol/mol. Cholesterol was dissolved in CHCl3/MeOH (2:1 v/v). The cholesterol solution was added to the dry lipid. A film of 2.5-5 mg lipid/glass vial was prepared by evaporating the solvents under a stream of nitrogen, followed by 3 h drying under high vacuum. SUV containing GSH were obtained by sonication according to Shin et al., 1996, as follows: GSH solution (0.2 M in 0.05 M NaCl, pH 7.0) was added to the dried film, mixed by vortex and sonicated for 10-30 min in a bath-type sonicator (G1125SP1, Laboratory Supplies Co. Inc., New York, NY). Final phospholipid concentration was either 5 or 10 mg/ml.
(i) Gel filtration Separation of SUV from free reagents was done by gel filtration on
Sephadex G-50 (15 ml bed volume) pre-equilibrated with 0.1 M NaCl in 0.01 M Na phosphate buffer (pH 7.0). Vesicles were eluted in the void volume and were monitored by absorption at 340 nm.
(j) Preparation of red blood cells (RBC)
Fresh human blood (in the presence of heparin) was washed three times with PBS. RBCs were collected after centrifugation (2000 rpm, 5 min) and resuspended in PBS. A 10% or 1% (vol/vol) suspension of RBC in PBS was used in the experiments.
(k) Electron spin resonance (ESR) experiments
Measurements were performed in a flat cell of the Bruker ER-200 D-SRC spectrometer. The experimental conditions included the following: field, 3500 G; sweep width, 100 G; receiver gain, 2x10^; microwave power, 20 mW; modulation amplitude, 0.8 G. DMPO was purified as described in Buettner and Oberley, 1978.
In experiments of hydroxyl radical generation, the sample contained H2O2 ( 1 mM), Feπ(EDTA)2 (0.8 mM ), DMPO (100 mM), in 20 mM sodium phosphate buffer (pH 7.4)) and NaCl (0.2 M), (final volume 0.2 ml) The hydroxyl radical formation was measured from the ESR spectrum of spin adduct DMPO-OH radical formed in the Fenton system.
(1) NMR Spectroscopy
NMR spectra were collected on a Bruker AMX-400 spectrometer. Analysis of allicin and CSSA structures was performed as described in Rabinkov et al., 1998. The product of the interaction between allicin and glutathione was isolated and dissolved in deuterated water and solutions of 10 mM were prepared. The pH was adjusted to 6.5 using KOD. ID *H (with water signal suppression) and 13 C spectra were collected at 25^ C. Structure analysis of the product obtained was performed as described previously (Miron et al., 1998; Rabinkov et al., 1998). Resonance multiplicities for *3C were established by acquiring DEPT spectra. For the DEPT sequence, the width of a 3C 90° pulse was 7ms, that of a }H 90° was 12.8 ms, and the (2J)"1 delay was set to 3.45 ms.
The 2D COSY45 H-1H shift-correlated spectra was recorded using a data size of 512 (tl)x 2048 (t2) with a spectral width of 1400 Hz. The HMQC spectra were recorded using a pulse sequence (invbtp in the Bruker software) which included the bilinear rotational decoupling (BIRD) pulse to invert the magnetization of protons not coupled to l^C. The spectra were collected with 2048 (t2) x 256 (tl) data points. Spectral widths of 1400 and 11000 Hz were used in the
F2 (IK) and FI ( ^C) domains, respectively. Data sets were multiplied in both dimensions by a 90°- shifted sine bell or Gaussian transformation function and generally zero-filled to 512 in tl dimension prior to Fourier transformation. The delay Di was set to 3.4 ms while D2 was empirically optimized at 600ms.
(m) Assay of antioxidant effect on lipid peroxides production (LPO) The preparation of fetal rat brain slices and the determination of LPO concentration in fetal rat brain slices by the thiobarbituric acid (TBA) method were conducted as described in Glozman and Yavin, 1997. Freshly prepared FeSθ4(7H2θ) was added to induce lipid peroxidation. Slices were routinely incubated for 15 min at 37° C with gentile shaking under permanent oxygen aeration. At the end of the incubation period, medium was separated from tissue by centrifugation at 3500x g for 5 min and 0.5 ml of medium was taken for TBARS content determination. Example 1. Reaction of allicin with GSH entrapped in SUV
Small unilamellar phospholipid vesicles (SUV) containing GSH were prepared in order to show allicin's propensity to permeate the lipid bilayer membrane. GSH, the main intracellular thiol of mammalian cells, is highly hydrophilic and therefore cannot pass lipid membranes.
The reaction between GSH and allicin was followed by HPLC and the product was characterized by 1H and 13C NMR (Table 1). The elution peak of the reaction product, GSSA (retention time 5.3 min), is positioned between that of allicin (retention time 8 min) and GSH (retention time 4.6 min) (Table 2). The kinetics of the reaction between GSH and allicin (-2: 1 ratio) in water is shown in Fig. 1. Formation of the product and disappearance of allicin were determined at various time intervals. The reaction was also monitored at different concentrations of allicin and GSH and at different temperatures. Bimolecular rate constant values for the reaction of allicin with GSH entrapped in phospholipid vesicles or in solution, calculated according to Reaction 1 above, are presented in Table 3.
Allicin reacts with GSH entrapped in liposomes at a high rate. The rate of GSSA formation in the vesicles (Table 3) was only slightly slower than in solution. The vesicle composition, DMPC or PC, shows no significant effect on allicin permeability. A decrease in temperature to less than 23°C, beloλv the phase transition of DMPC/cholesterol vesicles, did not hinder allicin penetration. These findings indicate that allicin permeates very easily through the lipid bilayers.
Table 1. *H and 13c NMR of GSSA in D?O at 298K
H2N_ _'uC02f
Table 2. HPLC analysis of the reaction mixture of GSH and CSSA with allicin.
Table 3. Bimolecular rate constants for the reaction of allicin with GSH: entrapped in phospholipid vesicles or in solution.
~ [GSH] Allicin Temperature (°C) K (M"1 s'"
10"JM 10'3M
Solution 0.22 0.80 4 26.28+1.25(3)
0.22 0.80 24 48.66 + 2.45(3)
0.42 0.58 35 88.13 + 5.32(3)
Vesicles: 0.18 2.90 10 21.29 + 2.20(2)
DMPC/cholesterol
3:1 mol/mol
0.34 1.35 15 23.38 ±2.75 (2)
0.34 1.35 24 33.57 + 4.95(2)
0.34 1.35 35 78.45 ±4.13 (2)
PC: cholesterol 0.16 1.92 24 30.40 ±2.47 (2)
5:1 mol/mol
0.11 0.68 24 31.28±3.15(2)
Reaction was performed in 0.1M NaCl, 0.01M Na phosphate buffer (pH 7.0). The results are the mean value of n independent experiments, where (n) represents the number of experiments, as is indicated in brackets. Example 2. Interaction of allicin with red blood cells; end products
Red blood cells (RBC) are naturally occurring membrane vesicles in which GSH is present at a concentration of 1-2 mM. The amount of thiols in PBS-washed human RBC was measured either by the noninvasive ESR technique with Biradical developed earlier by Weiner (1995), or directly after trichloroacetic acid (TCA) precipitation of the RBC and assay with DTNB at pH 7.0 (Table 4). The total concentration of thiol-containing compounds estimated by the two independent methods were very similar (about 2 mM) and are in a good agreement with data reported by others (Vina et al., 1995). The advantage of the ESR method is that it enables monitoring of the decrease of thiol concentration in cells after short exposure to allicin. Allicin (up to 2.5 x 10"5 M final concentration) was added to a 1% washed RBC suspension in an Eppendorf tube. After 1 -2 min at room temperature the Biradical was added (10"4 M final concentration) and the content of residual thiol concentration was monitored. As shown in Fig. 2, allicin penetrates through the RBC membrane and reacts with intracellular thiols in a concentration dependent manner
For the identification of the reaction products, washed human RBC were treated at 37° C with allicin (5x10"4 M). At different time intervals, a fresh solution of cysteine (20 mM final concentration) was added to block external allicin, and the suspension was washed three times with PBS. The washed RBC were treated with trichloroacetic acid (final concentration 5%), mixed by vortexing and centrifuged. The supernatant was diluted 1 : 12.5 with HPLC running buffer and analyzed by HPLC. The main product appeared as GSSA, which was formed immediately after allicin penetration into the RBC (Fig. 3). In this experiment, allicin was not in excess with respect to internal thiols. Table 4. Concentration of intracellular thiols (R-SH) determined in human RBC
* Assay of RSH was done after protein TCA precipitation of RBC suspension, and neutralization of the supernatant to pH 7.0 with NaOH. The results are means of three independent experiments.
Example 3. Synthesis and isolation of S-allylmercaptoglutathione (GSSA) GSSA was synthesized from glutathione (GSH) and allicin using an excess of allicin. GSH (200 mg in 5 ml water, pH 6.0) was added dropwise to allicin (130 mg), dissolved in 50% methanol (2 ml) and kept at room temperature for 2 hours . The product of the reaction was detected by HPLC analysis. Excess of allicin was removed by extraction with ether. The water phase was dried by lyophilization. The product was re-dissolved in water and dried again by lyophilization. The structure of GSSA was confirmed by Η and 13C NMR in D20 at 298K (Table 1) and MS (not shown). The elution pattern of the reaction product was as in Example 1 above (see Table 2).
Example 4. GSSA formation rate in the allicin/GSH mixture as a function of allicin concentration and of pH
GSH (1 mM) was incubated with allicin (0.7 mM to 1.3 mM) in 10 mM citrate phosphate buffer pH 5.0, at room temperature. The initial amount of GSSA produced was followed by HPLC analysis at different time intervals after dilution with HPLC acidic running buffer. The appearance of the product on HPLC during the reaction enabled us to follow the kinetic of interaction of allicin with GSH. The bimolecular kinetic constant of the reaction at pH 5 was determined at allicin concentrations of 0.7, 1.0 and 1.3 mM. The results are shown in Fig. 4 and in
Table 5. The kinetics of formation of GSSA in the allicin/GSH mixture was then determined at pH 6.0 and 7.0. Starting concentrations were GSH 0.25 mM and allicin 1.068 mM. At different time intervals, aliquots were diluted with 0.1% formic acid in 60% methanol, and assayed by HPLC. The results are shown in Fig.
Allicin (1 mM) was incubated with GSH (0.25 mM) in citrate-phosphate (10 mM) buffer at various pH: 4.5, 5, 5.5, 6. 6.5 and 7. The initial rate for each condition was followed at room temperature. The results are shown in Fig. 6. Each column represents the mean ± S.D. of three determinations done in the same pH.
As shown in Figs. 5 and 6, the rate of the reaction observed clearly indicates a strong dependence on pH. The pH dependence of the reaction rate indicates that GSH is involved in reaction with allicin in the form of mercaptide ion (GS").
Table 5. Rate of the reaction and kinetic constants of the reaction GSH/allicin at pH 5.0 and at room temperature
Example 5. SH-modifving activity of GSSA: Papain and TBAD inhibition
The SH-modifying activity of GSSA and CSSA was determined in the same enymatic systems as was described earlier for allicin (Rabinkov et al., 1998), namely, in SH-protease papain, where a SH-group (Cys25) Js located in the active site, and in alcohol dehydrogenase from the thermophylic bacteria Thermoanaerobium brockii (TBAD), where a SH-group (Cys20 ) }s located very close to the NADP+- binding site (Korkhin et al., 1998). According to X-ray data, the Cys25 of papain is located on the protein surface, on the groove between the two lobes of the protein, and therefore is available for chemical modification. Each TBAD subunit contains one free SH-group on the protein surface. Chemical modification of that group inhibits dramatically the enzymatic activity (Peretz et al., 1997; Rabinkov et al., 1998).
To test the inhibition of papain, DTT-activated and gel-filtered papain (papain-SH) was inactivated by GSSA (2.0 mM, 4.0 mM. 9.0 mM) in 50 mM Na acetate buffer pH 6.2 containing 2 mM EDTA. The residual activity of the inhibited enzyme was assayed at pH 6.5 and recorded as described in Material and Methods, section (d). Activity is expressed as % of enzyme activity of non- inhibited papain. As shown in Fig. 7, incubation of activated papain with GSSA led to rapid loss of enzymatic activity. The same results are obtained with CSSA (data not shown) as well as with allicin (Rabinkov et al, 1998). The loss of activity was time dependent. The rates of enzyme inactivation depend on the initial disulfide's concentration. As follows from these experiments, CSSA and GSSA, the natural products of allicin transformation, show pronounced SH modifying activity.
The kinetics of irreversible inhibition of the enzymes papain and TBAD by allicin, diallyl disulfide (DAD), GSSA and CSSA were evaluated according to Kits and Wilson, 1962. The kinetic constants for SH modification of papain and TBAD are presented in Tables 6 and 7, respectively. Allicin was more reactive, followed by CSSA and GSSA, which was the slowest due to its bulky glutathionyl moiety. Table 6. Analysis of irreversible inhibition of papain by allylmercapto derivatives.
Inhibitor k3 [min.'l] Kι[M]
Allicin 1.03 ±0.15 8.59x10-5 ±1.29x10-5
CSSA 0.69 ±0.14 4.13x10-3 ±0.83x10-3
DAD 1.03 ±0.20 2.20x10-2 ±0.33xl0-2
GSSA 1.38 ±0.22 7.58xl0-3± 1.25x10-3
Each point represents the mean value for n=3.
Table 7. Analysis of irreversible inhibition of TBAD by allylmercapto derivatives.
Inhibitor k3 [min.-1] Kl[M]
Allicin 0.405 ±0.15 1.30x10-3 ±0.30x10-3
CSSA 0.295 ±0.08 0.83x10-3 ±0.22x10-3
GSSA 0.09 ±0.04 0.91 xl0-3 ±0.15 xlO-3
Each point represents the mean value for n=3.
Example 6. Antioxidant activity of GSSA in vitro
The antioxidant properties of GSSA, CSSA and allicin were determined using the Fenton system as a source of hydroxyl radicals (Lloyd et al., 1997). H2O2 + Fe(II) *- OH + OH + Fe(III)
The rates of appearance and amount of hydroxyl radicals were determined with the spin trap DMPO that interacts with OH radicals at a high rate. The bimolecular rate constant for this interaction is 2x10^ M"l sec' (Finkelstein et al., 1980). We observed a spin adduct with a characteristic ESR spectrum: a quartet with intensity ratio 1:2:2:1 and hyperfme splitting constants aN =3.H = 14.9 G (Fig. 8A). This is a typical spectrum for a spin adduct of DMPO with -OH radical (Buettner, 1987).
As shown in Fig. 8B and Fig. 9, the addition of GSSA, CSSA or allicin to the samples decreased significantly the fonnation of DMPO-OH spin adduct, indicating a pronounced antioxidant activity of all three compounds. These data thus demonstrate that both GSSA and CSSA have high antioxidant properties. This mechanism explains the antioxidant activity of allicin even after its fast disappearance in 'real' biological systems.
Example 7. Effect of GSSA on LPO production by fetal rat brain slices ex vivo
The antioxidant activity of GSSA was investigated in tissues using fetal rat brain slices model ex vivo under iron-induced oxidative stress by determination of the lipid peroxides level as described in Materials and Methods, section (m). The effect of GSSA was compared with activities of alliin, allicin, GSH, GSSG, 2- deoxyribose and vitamin E. LPO production (%) in fetal rat brain slices was determined during 30 min incubation in presence of 0.1 mM of the various reagents by the TBA assay as described in Materials and Methods, section (m). As shown in Fig. 10, no significant antioxidant activity was observed after incubation of brain slices with alliin. In addition, no antioxidant activity was observed after 2 - deoxyribose or GSSG treatments (data not shown). In contrast, significant decrease of LPO production (p<0.05) was demonstrated under GSSA treatment. This antioxidant activity of GSSA is similar to the effects of GSH, about 30% decrease of TBARS production. Among all tested compounds, the most prominent inhibition of TBARS production (about 60%) was observed after allicin or vitamin E treatment.
The concentration curves for the antioxidant effect of GSSA, allicin, alliin and vitamin E on LPO production by fetal rat brain slices were examined. As shown in Fig. 11, the antioxidant effects of GSSA, allicin and vitamin E are dose dependent, whereas alliin does not demonstrate any antioxidant activity at all. However, the rate of inhibition of LPO production by allicin is similar to that of vitamin E, indicating that the lipid permeability of both is a factor responsible for inhibition of LPO production in this ex vivo model.
Example 8. Antiproliferative activity of GSSA Cell culture and cell proliferation assay
MCF-7 human mammary cancer cells were grown in DMEM medium containing 0.6 μg/ml insulin. The medium was supplemented with penicillin (10O U/ml), streptomycin (0.1 mg/ml) nystatin (12.5 μg/ml), and 10% FCS. Cells were seeded into 6-multiwell plates (170,000 cells per well) or 96-multiwell plates (5,000 cells per well) or 100 mm dish (1,500,00 cells per dish) in medium containing 3% FCS. One day later the medium was changed to one containing either only medium or allicin or GSSA, and the media were replaced daily. At the end of the incubation, 1.25 μCi/well of [ l J thymidine (specific radioactivity 5 μCi/mmol) was added for 1 hour. The nucleotide incorporation was stopped by adding unlabeled thymidine (0.5 μmol). The cells were then trypsinized and collected on a glass-fiber filter using a cell harvester (Inotech, Switzerland). Radioactivity was determined by a radioactive image analyzer (BAS 1000, Fuji, Japan).
As shown in Fig. 12, inhibition of proliferation was observed after treating the MCF-7 cells with either allicin (squares) or GSSA (diamonds). This inhibition was dose dependent. About 50% inhibition of proliferation was observed for both allicin and GSSA at 32 μM. When the MCF-7 human mammary cancer cells were treated with either allicin or GSSA at 32 μM, for several days, the observed inhibition of cell proliferation continuously increased and reached a plateau at about 50% inhibition after 3 days of treatment (Fig. 13). No significant differences were found between allicin and GSSA.
References
1. Angelides, KJ. and Fink, A.L. (1979) Mechanism of thiol protease catalysis: detection and stabilization of tetrahedral intermediate in papain catalysis, Biochemistry, 18: 2363-2369. 2. Ankri, S., Miron, T., Rabinkov, A., Wilchek, M. and Mirelman, D. (1997) Allicin from garlic strongly inhibits cysteine proteinases and cytopathic effects of Entamoeba histolytica., Antimicrob Agents Chemother., 41 : 2286-2288.
3. Buettner, G.R. and Oberley, L.W. (1978) Considerations in the spin trapping of superoxide and hydroxyl radical in aqueous systems using 5, 5- dimethyl-1-pyrroline- 1 -oxide, Biochem. Biophys. Res. Commun., 83: 69-74.
4. Buettner, G.R. (1987) Spin trapping: ESR parameters of spin adducts, Free Radic. Biol. Med., 3: 259-303.
5. Cavallito, C.J.and Bailey, J.H. (1944) Allicin, the antibacterial principle of Allium sativum. II. Isolation, physical properties and antibacterial action, J. Am.
Chem. Soc, 66: 1950-1951.
6. Chu, T.C., Ogidigben, M., Han, G. and DE, Potter. (1993) Allicin-induced hypotension in rabbit eyes, J Ocul Pharmacol, 9: 201-209.
7. Chu, T.C., Han, P., Han, G. and DE, Potter. (1999) Intraocular pressure lowering by S-allylmercaptocysteine in rabbits., J Ocul Pharmacol Ther, 15(1): 9-
17.
8. Degani, Y. and Patchornik, A. (1971) Selective cyanylation of sulfhydr l groups. II On the synthesis of 2-nitro-5-thiocyanatobenzoic acid, J. Org. Chem. , 36: 2727-2728. 9. Dirsch, V.M., Kiemer, A.K., Wagner, H. and Vollmar, A.M. (1998) Effect of Allicin and Ajoene, 2 Compounds of Garlic, on Inducible Nitric-Oxide Synthase, Atherosclerosis, 139: 333-339.
10. Feldberg, R.S., Chang, S.C., Kotik, A.N., Nadler, M., Neuwirth, Z., Sundstrom, D.C. and Thompson, N.H. (1988) In vitro mechanism of inhibition of bacterial cell growth by allicin, Antimicrob. Agents Chemother., 32: 1763-1768.
11. Finkelstein, E., Rosen, G.M. and Rauckman, E.J. (1980) Spin trapping of superoxide and hydroxyl radical: practical aspects, Arch. Bioch. Biophys., 200: 1- 16.
12. Freeman, F. and Kodera, Y. (1995) Garlic Chemistry - Stability of S-(2- Propenyl) 2-Propene-l-Sulfinothioate (Allicin) in Blood, Solvents, and Simulated
Physiological Fluids., J. Agricultural and Food Chem., 43: 2332-2338. 13. Glozman, S. and Yavin, E. (1997) Lipid peroxides are generated by the fetal rat brain after episodes of global ischemia in utero, Neurochemical Research, 22: 201-208.
14. Imai, J., Ide, N., Nagae, S., Moriguchi, T., Matsuura, H. and Itakura, Y. (1994) Antioxidant and radical scavenging effects of aged garlic extract and its constituents., Planta Med., 60(5): 417-420.
15. Kitz, R. and Wilson, LB. (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase, J. Biol. Chem., 237: 3245-3249.
16. Koch, H.P. and Lawson, L.D. (1996) Garlic: The science and therapeutic application of Allium sativum L. and related species, 2nd edn., Williams &
Wilkins, Baltimore, MD, USA.
17. Korkhin, Y., Kalb(Gilboa), A.J., Peretz, M., Bogin, O., Burstein, Y. and Frolow, F. (1998) NADP-dependent Bacterial Alcohol Dehydrogenases: Crystal structure, cofactor-binding and cofactor specificity of the ADHs of Clostridium beijerinckii and Thermoanaerobacter brockii, J. Mol. Biol., 278: 967-981.
18. Lawson, L.D. and Wang, Z.J. (1993) Pre-hepatic fate of the organosulfur compounds derived from garlic (Allium sativum), Planta Med. Suppl., 59: A688- A689.
19. Lee, E.S., Steiner, M. and Lin, R. (1994) Thioallyl compounds: potent inhibitors of cell proliferation., Biochim Biophys Acta, 1221(1): 73-77.
20. Lloyd, R.V., Hanna, P.M. and Mason, R.P. (1997) The origin of the hydroxyl radicals in the Fenton reaction, Free Radic. Biol. Med., 22: 885-888.
21. Miron, T., Rabinkov, A., Mirelman, D., Weiner, L. and Wilchek, M. (1998) A spectrophotometric assay for allicin and alliinase (Alliin lyase) activity: reaction of 2-nitro-5-thiobenzoate with thiosulfinates., Anal Biochem., 265: 317-325.
22. Peretz, M. and Burstein, Y. (1989) Amino acid sequence of alcohol dehydrogenase from thennophilic bacterium Thermoanaerobium brockii, Biochemistry, 28: 6549-6555.
23. Peretz, M., Weiner, L.M. and Burstein, Y. (1997) Cysteine reactivity in Thermoanaerobacter brockii alcohol dehydrogenase, Protein Science, 6: 1074-
1083. 24. Pinto, J.T., Qiao, C, Xing, J., Rivlin, R.S., Protomastro, M.L., Weissler, M.L., Tao, Y., Thaler, H. and Heston, W.D. (1997) Effects of garlic thioallyl derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture., Am J Clin Nutr, 66(2): 398-405. 25. Prasad, K., Laxdal, V.A., Yu, M. and Raney, B.L. (1995) Antioxidant Activity of Allicin, an Active Principle in Garlic, Molecular and Cellular Biochemistry, 148: 183-189.
26. Rabinkov, A., Miron, T., Konstantinovski, L., Wilchek, M., Mirelman, D. and Weiner, L. (1998) The mode of action of allicin: trapping of radicals and interaction with thiol containing proteins, Biochim. Biophys. Acta, 1379: 233 -244.
27. Shin, I., Silman, I. and Weiner, L. (1996) Interaction of partially unfolded forms of Torpedo acetylcholinesterase with liposomes. Protein Sci. 5: 42-51.
28. Sigounas, G., Hooker, J.L., Li, W., Anagnostou, A. and Steiner, M. (1997a) S-allylmercaptocysteine, a stable thioallyl compound, induces apoptosis in erythroleukemia cell lines., Nutr Cancer, 28(2): 153-9.
29. Sigounas, G., Hooker, J., Anagnostou, A. and Steiner, M. (1997b) S- allylmercaptocysteine inhibits cell proliferation and reduces the viability of erythroleukemia, breast, and prostate cancer cell lines., Nutr Cancer, 27(2): 186- 191. 30. Vina, J., Sastre, J., Asensi, M. and Packer, L. (1995) Assay of blood glutathione oxidation during physical exercise, Methods Enzymol., 251 : 237-243. 31. Weiner, L.M. (1995) Quantitative determination of thiol groups in low and high molecular weight compounds by electron paramagnetic resonance, Meth. Enzymol., 251 : 87-105. 32. Wills, E.D. (1956) Enzyme inhibition by allicin, the active principle of garlic, Biochem. J, 63: 514-520.

Claims

CLAIMS:
1. S-Allylmercaptoglutathione of the formula:
H2NCHCH2CH2CONHCHCONHCH2COOH
I I
COOH CH2-S-S-CH2-CH=CH2
and salts thereof.
2. A method for the preparation of S-allylmercaptoglutathione which comprises reacting glutathione with allicin or with diallyl disulfide.
3. A pharmaceutical composition comprising S-allylmercaptoglutathione or a salt thereof and a pharmaceutically acceptable carrier.
4. The pharmaceutical compositions according to claim 3 for the treatment of atherosclerosis, coronary artery diseases, thrombosis, high levels of cholesterol and blood lipids, high blood pressure, control of weight, Alzheimer disease, glaucoma, cancer and inflammatory disorders.
EP00976230A 1999-11-16 2000-11-16 S-allylmercaptoglutathione and uses thereof Withdrawn EP1230259A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL13297199A IL132971A0 (en) 1999-11-16 1999-11-16 Glutathione derivative its preparation and pharmaceutical compositions comprising it
IL13297199 1999-11-16
PCT/IL2000/000761 WO2001036450A1 (en) 1999-11-16 2000-11-16 S-allylmercaptoglutathione and uses thereof

Publications (1)

Publication Number Publication Date
EP1230259A1 true EP1230259A1 (en) 2002-08-14

Family

ID=11073492

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00976230A Withdrawn EP1230259A1 (en) 1999-11-16 2000-11-16 S-allylmercaptoglutathione and uses thereof

Country Status (6)

Country Link
EP (1) EP1230259A1 (en)
JP (1) JP2003514830A (en)
AU (1) AU1410401A (en)
CA (1) CA2391969A1 (en)
IL (1) IL132971A0 (en)
WO (1) WO2001036450A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217084B2 (en) 2004-05-24 2012-07-10 Allium Vitalis Incorporated Medicinal products incorporating bound organosulfur groups
JP2011078357A (en) * 2009-10-07 2011-04-21 Kochi Univ Method for fractional determination of vitamin b6 and kit for fractional determination of vitamin b6
CZ308144B6 (en) * 2014-05-09 2020-01-22 Fakultní nemocnice Hradec Králové Process for preparing S-allylthioglutathione, optionally in admixture with S-allyldithioglutathione, mixture of S-allylthioglutathione with S-allyldithioglutathione and S-allyldithioglutathione
KR102464435B1 (en) * 2020-09-22 2022-11-07 의료법인 성광의료재단 Composition for preventing or treating inflammatory diseases comprising D-glutathione or derivatives thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0782144A (en) * 1993-09-09 1995-03-28 Fuji Sangyo Kk Antiallergic agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0136450A1 *

Also Published As

Publication number Publication date
JP2003514830A (en) 2003-04-22
WO2001036450A1 (en) 2001-05-25
CA2391969A1 (en) 2001-05-25
AU1410401A (en) 2001-05-30
IL132971A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
Rabinkov et al. S-Allylmercaptoglutathione: the reaction product of allicin with glutathione possesses SH-modifying and antioxidant properties
Miron et al. The mode of action of allicin: its ready permeability through phospholipid membranes may contribute to its biological activity
Rabinkov et al. The mode of action of allicin: trapping of radicals and interaction with thiol containing proteins
Castilho et al. Permeabilization of the inner mitochondrial membrane by Ca2+ ions is stimulated by t-butyl hydroperoxide and mediated by reactive oxygen species generated by mitochondria
Stocker et al. Antioxidant activity of albumin-bound bilirubin.
Schauenstein et al. Formation and properties of reactive aldehydes
EP2018149A1 (en) Cosmetic active ingredient composed of arginine ferrulate and a microalgae extract and its uses
JP2003519191A (en) Methods for obtaining thylakoids from photosynthetic organisms, plant fractions obtained therefrom, pure thylakoids, and methods of using thylakoids as ROS scavengers, photoprotectors, biosensors, biofilters and bioreactors
Becker et al. [15] 1, 3-Bis (2-chloroethyl)-1-nitrosourea as Thiol-carbamoylating agent in biological Systems
Takebayashi et al. Inhibition of free radical-induced erythrocyte hemolysis by 2-O-substituted ascorbic acid derivatives
Nagase et al. Biosynthesis of methylguanidine in isolated rat hepatocytes and in vivo
FR2747044A1 (en) USE OF POST-GERMINATING VEGETABLE SEEDS AS A SOURCE OF SUPEROXIDE DISMUTASE AND COSMETIC, PHARMACEUTICAL OR AGRO-FOOD COMPOSITIONS CONTAINING SUCH SUPEROXIDE DISMUTASE VEGETABLE, AND METHOD OF EXTRACTING
JP6868611B2 (en) How to Obtain Superoxide Dismutase (SOD) -rich Tetracermis Chui Microalgae Biomass
US5277908A (en) Modified superoxide dismutase
Sugawara et al. Generation of oxygen free radicals in thyroid cells and inhibition of thyroid peroxidase
AU701529B2 (en) NADH oxidase as a target in diagnosis and therapy
FR3035799A1 (en) SUPPORT FOR THE PURIFICATION OF BIOLOGICAL LIQUIDS
JP2008024600A (en) Inhibitor for acrolein adduct formation, skin anti-aging external preparation and anti-aging food and beverage containing the same
EP1230259A1 (en) S-allylmercaptoglutathione and uses thereof
Moldéus et al. Turnover of Cellular Glutathione in Isolated Rat‐Kidney Cells: Role of Cystine and Methionine
FR2929957A1 (en) Metal-phycocyanin comprising combination of protein constituent of cyanobacteria, and phycocyanin, with a divalent metal e.g. chromium and copper, useful for the preparation of compositions e.g. for micro-nutrition and cosmetics
Kneifel Amines in algae
JP4944372B2 (en) Acrolein adduct formation inhibitor, and skin external preparation and health supplement containing the same
US20060093684A1 (en) Seleniferous composition for producing antioxidase in vivo
Lakshmi et al. Modification of mercury-induced biochemical alterations by Triticum Aestivum Linn in rats

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20020516

17Q First examination report despatched

Effective date: 20021031

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040221